MENU

Remdesivir for the Treatment of Covid-19-Final Report

Beigel, JH; Tomashek, KM; Dodd, LE; Mehta, AK; Zingman, BS; Kalil, AC; Hohmann, E; Chu, HY; Luetkemeyer, A; Kline, S; de Castilla, DL; Finberg, RW; Dierberg, K; Tapson, V; Hsieh, L; Patterson, TF; Paredes, R; Sweeney, DA; Short, WR; Touloumi, G; Lye, DC;

NEW ENGLAND JOURNAL OF MEDICINE
2020
VL / 383 - BP / 1813 - EP / 1826
abstract
BackgroundAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. MethodsWe conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. ResultsA total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). ConclusionsOur data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.) In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receiving low-flow oxygen at baseline.
1st Global

AccesS level

Bronze, Green Published

Mentions data

PAPER MENTIONS
Clinical Medicine
  •   Twitter
  • 13.6K
  •   Wikipedia
  • 2
  •   News
  • 1.4K
  •   Policy
  • 20
Global Ranking
  •   Twitter
  • 13.6K
  •   Wikipedia
  • 2
  •   News
  • 1.4K
  •   Policy
  • 20

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 13.6K
  •   Wikipedia
  • 2
  •   News
  • 1.4K
  •   Policy
  • 20
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00